Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

The role of Fli-1 in normal cell function and malignant transformation

Abstract

Aberrant expression of the Fli-1 transcription factor following genetic mutation has been recognized as a seminal event in the initiation of certain types of malignant transformation. Indeed, the etiology of a number of virally induced leukemias, including Friend virus-induced erythroleukemia, has been associated with Fli-1 overexpression. The clinical relevance of Fli-1 becomes apparent in human Ewing's sarcoma in which Fli-1 is the target of a characteristic chromosomal translocation. As such, Fli-1 has generated considerable interest over the past several years for its role in malignant transformation and tumor progression. This review will present a synopsis of the current research on Fli-1 with emphasis on its function in malignant transformation. Moreover, the possible role of Fli-1 in cellular proliferation, differentiation and survival, as well as the recent development of transgenic and knock-out mice to investigate the function of Fli-1 will be discussed. Finally, the significance of identifying target genes that are regulated by Fli-1 and their role in cellular function will be reviewed.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  • Arvand A, Bastians H, Welford SM, Thompson AD, Ruderman JV and Denny CT. . 1998 Oncogene 17: 2039–2045.

  • Athanasiou M, Clausen PA, Mavrothalassitis GJ, Zhang XK, Watson DK and Blair DG. . 1996 Cell. Growth. Differ. 7: 1525–1534.

  • Athanasiou M, Mavrothalassitis G, Sun-Hoffman L and Blair DG. . 2000 Leukemia 14: 439–445.

  • Bailly RA, Bosselut R, Zucman J, Cormier F, Delattre O, Roussel M, Thomas G and Ghysdael J. . 1994 Mol. Cell. Biol. 14: 3230–3241.

  • Barbeau B, Barat C, Bergeron D and Rassart E. . 1999 Oncogene 18: 5535–5545.

  • Barbeau B, Bergeron D, Beaulieu M, Nadjem Z and Rassart E. . 1996 Biochim. Biophys. Acta. 1307: 220–232.

  • Bastian LS, Kwiatkowski BA, Breininger J, Danner S and Roth G. . 1999 Blood 93: 2637–2644.

  • Ben-David Y and Bernstein A. . 1991b Cell 66: 831–834.

  • Ben-David Y, Giddens EB and Bernstein A. . 1990 Proc. Natl. Acad. Sci. USA 87: 1332–1336.

  • Ben-David Y, Giddens EG, Letwin K and Bernstein A. . 1991a Genes Dev. 5: 908–918.

  • Bergeron D, Poliquin L, Kozak CA and Rassart E. . 1991 J. Virol. 65: 7–17.

  • Brown LA, Rodaway AR, Schilling TF, Jowett T, Ingham PW, Patient RK and Sharrocks AD. . 2000 Mech. Dev. 90: 237–252.

  • Dalgleish P and Sharrocks AD. . 2000 Nucleic Acids Res. 28: 560–569.

  • Darby TG, Meissner JD, Ruhlmann A, Mueller WH and Scheibe RJ. . 1997 Oncogene 15: 3067–3082.

  • Delattre O, Zucman J, Melot T, Garau XS, Zucker JM, Lenoir GM, Ambros PF, Sheer D, Turc-Carel C and Triche TJ. . 1994 N. Engl. J. Med. 331: 294–299.

  • Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M, Kovar H, Joubert K, de Jong P, Rouleau G, Aurias A and Thomas G. . 1992 Nature 359: 162–165.

  • Denicourt C, Edouard E and Rassart E. . 1999 J. Virol. 73: 4439–4442.

  • Deramaudt BM, Remy P and Abraham NG. . 1999 J. Cell. Biochem. 72: 311–321.

  • Deveaux S, Filipe A, Lemarchandel V, Ghysdael J, Romeo PH and Mignotte V. . 1996 Blood 87: 4678–4685.

  • Dhulipala PD, Lee L, Rao VN and Reddy ES. . 1998 Oncogene 17: 1149–1157.

  • Gobel MG, Moreau-Gachelin F, Ray D, Tambourin P, Tavitian A, Klemsz MJ, McKercher SC, Van Beveren C and Maki RA. . 1990 Cell 61: 1165–1166.

  • Golub TR, Barker GF, Lovett M and Gilliland DG. . 1994 Cell 77: 307–316.

  • Hahm KB, Cho K, Lee C, Im YH, Chang J, Choi SG, Sorensen PH, Thiele CJ and Kim SJ. . 1999 Nat. Genet. 23: 222–227.

  • Hart A, Melet F, Grossfeld P, Chien K, Jones C, Tunnacliffe A, Favier R and Bernstein A. . 2000 Immunity 13: 167–177.

  • Hipskind RA, Rao VN, Mueller CG, Reddy ESP and Nordheim A. . 1991 Nature 354: 531–534.

  • Howard JC, Berger L, Bani MR, Hawley R and Ben-David Y. . 1996 Oncogene 12: 1405–1415.

  • Howard JC, Yousefi S, Cheong G, Bernstein A and Ben-David Y. . 1993 Oncogene 8: 2721–2729.

  • Jaishankar S, Zhang J, Roussel MF and Baker SJ. . 1999 Oncogene 18: 5592–5597.

  • Klemsz MJ, Maki RAPT, Moore J and Hromas R. . 1994 J. Biol. Chem. 268: 5769–5773.

  • Kwiatkowski BA, Bastian LS, Bauer TR, Tsai S, Zielinska-Kwiatkowska AG and Hickstein DD. . 1998 J. Biol. Chem. 273: 17525–17530.

  • Leprince DA, Gegonne A, Coll J, de Taisne C, Schneeberger A, Lagrou C and Stehelin D. . 1983 Nature 306: 395–397.

  • Liang H, Mao X, Olejniczak ET, Nettesheim DG, Yu L, Meadows RP, Thompson CB and Fesik SW. . 1994a Nat. Struct. Biol. 1: 871–875.

  • Liang H, Olejniczak ET, Mao X, Nettesheim DG, Yu L, Thompson CB and Fesik SW. . 1994b Proc. Natl. Acad. Sci. USA 91: 11655–11659.

  • Lin PP, Brody RI, Hamelin AC, Bradner JE, Healey JH and Ladanyi M. . 1999 Cancer Res. 59: 1428–1432.

  • Mager AM, Grapin-Botton A, Ladjali K, Meyer D, Wolff CM, Stiegler P, Bonnin MA and Remy P. . 1998 Int. J. Dev. Biol. 42: 561–572.

  • Mao X, Miesfeldt S, Yang H, Leiden JM and Thompson CB. . 1994 J. Biol. Chem. 269: 16216–16222.

  • May WA, Arvand A, Thompson AD, Braun BS, Wright M and Denny CT. . 1997 Nat. Genet. 17: 495–497.

  • May WA, Lessnick SL, Braun BS, Klemsz M, Lewis BC, Lunsford LB, Hromas R and Denny CT. . 1993 Mol. Cell. Biol. 13: 7393–7398.

  • Melet F, Motro B, Rossi DJ, Zhang L and Bernstein A. . 1996 Mol. Cell. Biol. 16: 2708–2715.

  • Moreau-Gachelin F, Tavitian A and Tambourin P. . 1988 Nature 331: 277–280.

  • Ott DE, Keller J and Rein A. . 1994 Virology 205: 563–568.

  • Pereira R, Quang CT, Lesault I, Dolznig H, Beug H and Ghysdael J. . 1999 Oncogene 18: 1597–1608.

  • Peter M, Magdelenat H, Michon J, Melot T, Oberlin O, Zucker JM, Thomas G and Delattre O. . 1995 Br. J. Cancer 72: 96–100.

  • Petermann R, Mossier BM, Aryee DN, Khazak V, Golemis EA and Kovar H. . 1998 Oncogene 17: 603–610.

  • Pfleiderer C, Zoubek A, Gruber B, Kronberger M, Ambros PF, Lion T, Fink FM, Gadner H and Kovar H. . 1995 Int. J. Cancer 64: 135–139.

  • Prasad DD, Rao VN and Reddy ES. . 1992 Cancer Res. 52: 5833–5837.

  • Price MA, Rogers AE and Treisman R. . 1995 EMBO J. 14: 2589–2601.

  • Rao VN, Ohno T, Prasad DD, Bhattacharya G and Reddy ES. . 1993 Oncogene 8: 2167–2173.

  • Rivera RR, Stuiver MH, Steenbergen R and Murre C. . 1993 Mol. Cell. Biol. 13: 7163–7169.

  • Rowley JD. . 1999 Semin. Hematol. 36: 59–72.

  • Rubnitz JE, Pui CH and Downing JR. . 1999 Leukemia 13: 6–13.

  • Sarrazin S, Starck J, Gonnet C, Doubeikovski A, Melet F and Morle F. . 2000 Mol. Cell. Biol. 20: 2959–2969.

  • Selleri L, Giovannini M, Romo A, Zucman J, Delattre O, Thomas G and Evans GA. . 1994 Cytogenet. Cell. Genet. 67: 129–136.

  • Sels FT, Langer S, Schulz AS, Silver J, Sitbon M and Friedrich RW. . 1992 Oncogene 7: 643–652.

  • Seth A, Giunta S, Franceschil C, Kola I and Venanzoni MC. . 1999 Cell Death Differ. 6: 902–907.

  • Seth A, Robinson L, Thompson DM, Watson DK and Papas TS. . 1993 Oncogene 8: 1783–1790.

  • Shirasaki F, Makhluf, HA, LeRoy, C, Watson, D and Trojanowska, M. . 1999 Oncogene 18: 7755–7764.

  • Silver J and Kozak C. . 1986 J. Virol. 57: 526–533.

  • Spyropoulos DD, Pharr PN, Lavenburg KR, Jackers P, Papas TS, Ogawa M and Watson DK. . 2000 Mol. Cell. Biol. 20: 5643–5652.

  • Starck J, Doubeikovski A, Sarrazin S, Gonnet C, Rao G, Skoultchi A, Godet J, Dusanter-Fourt I and Morle F. . 1999 Mol. Cell. Biol. 19: 121–135.

  • Szymczyna BR and Arrowsmith, CH. . 2000 J. Biol. Chem. 275: 28363–28370.

  • Tamir A, Howard J, Higgins RR, Li YJ, Berger L, Zacksenhaus E, Reis M and Ben-David Y. . 1999 Mol. Cell. Biol. 19: 4452–4464.

  • Thompson AD, Braun BS, Arvand A, Stewart SD, May WA, Chen E, Korenberg J and Denny C. . 1996 Oncogene 13: 2649–2658.

  • Watson DK, Robinson L, Hodge DR, Kola I, Papas TS and Seth A. . 1997 Oncogene 14: 213–221.

  • Watson DK, Smyth FE, Thompson DM, Cheng JQ, Testa JR, Papas TS and Seth A. . 1992 Cell Growth Differ. 3: 705–713.

  • Yi H, Fujimura Y, Ouchida M, Prasad DD, Rao VN and Reddy ES. . 1997 Oncogene 14: 1259–1268.

  • Zhang L, Eddy A, Teng T, Fritzler M, Kluppel M, Melet F and Bernstein A. . 1995 Mol. Cell. Biol. 15: 6961–6970.

  • Zhang L, Lemarchandel V, Romeo P-H, Ben-David Y and Bernstein A. . 1993 Oncogene 8: 1621–1630.

  • Zochodne B, Truong AH, Stetler K, Higgins RR, Howard J, Dumont D, Berger SA and Ben-David Y. . 2000 Oncogene 19: 2296–2304.

Download references

Acknowledgements

This review is dedicated to Dr Takis S Papas who is a pioneer in the field and whose contributions have been instrumental in the discovery and understanding of the Ets family of transcription factors. The authors would like to thank Dr Brian Pak, Dr Rachel Higgins, Jennifer Tran and Zubin Master for their comments on the manuscript. This work is supported in part by grants from National Cancer Institute of Canada and Medical Research Council of Canada to Y Ben-David.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Truong, A., Ben-David, Y. The role of Fli-1 in normal cell function and malignant transformation. Oncogene 19, 6482–6489 (2000). https://doi.org/10.1038/sj.onc.1204042

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204042

Keywords

This article is cited by

Search

Quick links